Jimini Health Raises $17M Seed for Supervised AI Therapy
Jimini Health, a New York-based developer of clinician-supervised AI for behavioral health, has raised $17M in seed funding led by M13. The company's Sage platform acts as an AI care team member, delivering 24/7 patient support between therapy sessions while keeping clinicians in control. The capital will scale Sage for partnerships with large behavioral health providers.
Behavioral Health AI Funding Surges
The round comes amid a funding wave in AI-augmented behavioral health. Blossom Health raised $20M in March 2026 for its AI psychiatry copilot, while Ease Health secured $41M out of stealth the same month per Crain's New York. Jimini differentiates with full clinician oversight on every patient interaction, addressing gaps in standalone tools.
Unsupervised AI Risks Escalate
More than 5.4 million U.S. adolescents and young adults already use AI chatbots for mental health support per Behavioral Health Business. Weekly, 1 million people discuss suicide with ChatGPT, a tool not designed for such crises per HIT Consultant. These unsupervised interactions highlight systemic risks amid clinician shortages and rising demand for continuous care.
Sage Augments Clinician Workflows
Sage integrates with electronic health records, follows clinician care plans, and escalates risks in real-time. Unlike documentation-focused tools like Eleos Health $125M+ raised, Sage provides direct patient engagement. The platform supports measurement-based care and ensures audit-readiness for organizations.
As M13's Morgan Blumberg noted:
"When 1 million people a week are discussing suicide with a product that was never designed to handle it, that’s not an edge case, it’s a systemic gap."
Investor Blend Signals Validation
M13, Town Hall Ventures, LionBird Venture Partners, Zetta Venture Partners, and nonprofit One Mind participated. Town Hall brings behavioral health expertise from bets like Eleanor Health, while Zetta adds AI infrastructure conviction. This mix underscores scalability for supervised AI in regulated settings.
AI Mental Health Market Expands
The AI mental health market stands at $1.71B in 2025, projected to reach $9.12B by 2033 at 23.29% CAGR per Grand View Research. Competitors include Woebot Health $123M for chatbots and Spring Health $466M for matching platforms. Jimini's clinician-in-loop model aligns with FDA's relaxed oversight on low-risk AI per STAT.
Ex-Immunai Founders Drive Expertise
Co-founder and CEO Luis Voloch, ex-CTO of $295M+ AI-biotech Immunai, holds MIT degrees in EECS and Math. President Mark Jacobstein boasts exits like iSkoot to Qualcomm and Guardant Health IPO. CPO Sahil Sud was founding VP Product at Ribbon Health, acquired by H1.
Luis Voloch, CEO, explained:
"Patients are already using general-purpose AI for mental health support between appointments without any clinician oversight."
Partnerships Scale Supervised Care
Jimini operates its own clinic for real-world testing and eyes reimbursable deployments via CMS frameworks. The funding accelerates Sage rollouts with major health systems, building on pilots and safety frameworks released in 2025.